Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 1.00 (7.407%)
Open: 14.00
High: 14.00
Low: 14.00
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Synature Ltd

15 Nov 2005 07:03

Angle PLC15 November 2005 For immediate release 15 November 2005 ANGLE plc ("ANGLE") SENIOR APPOINTMENTS AND VENTURE UPDATE ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce two senior appointments at its venture company, SynatureLtd. Founded earlier this year, Synature Ltd (formerly known as Customiser Group Ltd)provides psychological profiling tools that engage the consumer, deliveringinsight into individual attitudes and consumer preferences complementingtraditional demographic models. Based in Guildford Surrey, Synature Ltd is oneof ANGLE's eight venture companies. Dr. John Woods joins Synature Ltd as Chief Executive Officer. Previously founderand Chief Executive of Site Intelligence Ltd, one of the UK's most successfulweb analytics companies, John has worked with clients such as Argos, Expedia,SAP and Lloyds TSB. Dr. Woods has 15 years' experience in commercialisation and marketing ofadvanced software technologies. He holds a doctorate from Jesus College, Oxfordand an MBA. Commenting on his appointment, Dr. Woods said "I am delighted to be joining the Synature team at this exciting stage in thecompany's development. Marketing departments have a growing appetite forenhanced profiling and targeting of online and offline customers. Synature'sunique intellectual property offers a compelling way to meet that need.Moreover, ANGLE provides Synature with a supportive environment in which thatcompelling intellectual property can be rapidly and successfully commercialised." Professor William J. Fitzgerald joins Synature Ltd as a consultant technicaladvisor. He is Professor of Applied Statistics and Signal Processing and Headof the Signal Processing and Communications Laboratory at the University ofCambridge. He consults for a number of successful high technology companies inboth the UK and USA. Professor Fitzgerald commented: "Synature's consumer profiling techniques demonstrate the real world businessbenefits that can be obtained from state-of-the-art data analysis and patternrecognition. I am excited to be part of the team and to be ensuring thatSynature's clients receive maximum insight and maximum value from theapplication of our technologies." Stephen Bence, Director of New Ventures at ANGLE, added: "These two key appointments complement Synature's existing founding team andprovide the company with additional commercial and technical expertise. We areexcited about the opportunity that Synature's unique intellectual propertyrepresents." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Synature Ltd 08701 909550John Woods, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com Synature Ltd is an ANGLE Technology group company formed to commercialiseintellectual property acquired in 2005 from Customiser Ltd. Synature'sintellectual property provides unique ways to profile consumers in terms oftheir underlying preferences. The resulting profiles allow fine-grainedconsumer segmentation that complements traditional demographics. Synature'stechniques can be applied both online and offline. Further information can be found on www.synature.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.